James Shannon Net Worth

The estimated Net Worth of James Samuel Shannon is at least $4.36 Million dollars as of 29 September 2023. James Shannon owns over 11,850 units of Horizon Therapeutics Plc stock worth over $3,856,043 and over the last 15 years he sold HZNP stock worth over $0. In addition, he makes $507,237 as Independent Director at Horizon Therapeutics Plc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

James Shannon HZNP stock SEC Form 4 insiders trading

James has made over 8 trades of the Horizon Therapeutics Plc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 11,850 units of HZNP stock worth $144,452 on 29 September 2023.

The largest trade he's ever made was exercising 25,000 units of Horizon Therapeutics Plc stock on 12 September 2019 worth over $304,750. On average, James trades about 3,104 units every 53 days since 2010. As of 29 September 2023 he still owns at least 33,156 units of Horizon Therapeutics Plc stock.

You can see the complete history of James Shannon stock trades at the bottom of the page.

James Shannon biography

Dr. James Samuel Shannon M.D., is Independent Director of the Company. Dr. Shannon currently serves on the board of directors of MannKind Corporation, a public biopharma company focused on treatments for diabetes, and ProQR Therapeutics NV, a public biotechnology company. From May 2012 to March 2015, Dr. Shannon served as the chief medical officer of GlaxoSmithKline (GSK), Prior to that, Dr. Shannon spent more than a decade with Novartis, a public pharmaceutical company. In his last role with the company, as global head of pharma development, he was responsible for all of Novartis’s development activities, from pre-clinical through Phase 4 and oversaw an annual development budget of approximately $4 billion. Dr. Shannon received his science and medical degrees from Queen’s University in Belfast, Northern Ireland. He also serves as chairman of the board of directors of Kyowa Kirin (NA), a private biopharma company and subsidiary of Kyowa Kirin, and on the boards of directors of Immodulon Therapeutics Limited, a private biopharma company, and MyTomorrows, a private health-based platform that collaborates with drug developers to provide early access to treatments for patients who have exhausted all other options.

What is the salary of James Shannon?

As the Independent Director of Horizon Therapeutics Plc, the total compensation of James Shannon at Horizon Therapeutics Plc is $507,237. There are 11 executives at Horizon Therapeutics Plc getting paid more, with Timothy Walbert having the highest compensation of $13,873,200.

How old is James Shannon?

James Shannon is 63, he's been the Independent Director of Horizon Therapeutics Plc since 2017. There are 5 older and 19 younger executives at Horizon Therapeutics Plc. The oldest executive at Horizon Therapeutics Plc is William Daniel, 67, who is the Independent Director.

What's James Shannon's mailing address?

James's mailing address filed with the SEC is 1, Casper Street, Danbury, Fairfield County, Connecticut, 06810, United States.

Insiders trading at Horizon Therapeutics Plc

Over the last 13 years, insiders at Horizon Therapeutics Plc have traded over $454,905,275 worth of Horizon Therapeutics Plc stock and bought 11,809,010 units worth $58,823,653 . The most active insiders traders include Jeff Himawan, Woodlands Health Ventures F..., and Jean Francois Formela. On average, Horizon Therapeutics Plc executives and independent directors trade stock every 13 days with the average trade being worth of $12,248,018. The most recent stock trade was executed by Gino Santini on 2 October 2023, trading 23,092 units of HZNP stock currently worth $351,691.

What does Horizon Therapeutics Plc do?

at horizon therapeutics, we believe science and compassion must work together to transform lives. we are driven to deliver innovative medicines to those living with rare, autoimmune and severe inflammatory diseases because we uniquely understand the patient journey. for us, success is measured by the numbers that matter most – the number of lives we touch, the number we change and those we work to help save.

Complete history of James Shannon stock trades at Horizon Therapeutics Plc and Mannkind Corp

Horizon Therapeutics Plc executives and stock owners

Horizon Therapeutics Plc executives and other stock owners filed with the SEC include:

• Timothy Walbert,
  Chairman of the Board, President, Chief Executive Officer
• Timothy P. Walbert,
  Chairman, Pres & CEO
• Barry Moze,
  Executive Vice President, Chief Administrative Officer
• Paul Hoelscher,
  Chief Financial Officer, Executive Vice President
• Vikram Karnani,
  Executive Vice President, President - International
• Paul W. Hoelscher,
  Exec. VP & CFO
• Andy Pasternak,
  Exec. VP & Chief Strategy Officer
• Dr. Jeffrey W. Sherman F.A.C.P., FACP, M.D.,
  Exec. VP & Chief Medical Officer
• Michael Grey,
  Lead Independent Director
• Jeffrey Himawan,
  Independent Director
• H. Thomas Watkins,
  Independent Director
• James Shannon,
  Independent Director
• William Daniel,
  Independent Director
• Pascale Witz,
  Independent Director
• Susan Mahony,
  Independent Director
• Irina Konstantinovsky,
  Chief Human Resource Officer, Executive Vice President
• Daniel Camardo,
  Executive Vice President, President - U.S.
• Jeffrey Kent,
  Senior Vice President, Head of Medical Affairs and Outcomes Research
• Andy Pasternak,
  Executive Vice President, Chief Business Officer
• Geoffrey Curtis,
  Executive Vice President - Corporate Affairs, Chief Communications Officer
• Tina Ventura,
  Senior Vice President, Investor Relations
• Michael DesJardin,
  Executive Vice President - Technical Operations and Corporate Quality
• Brian Beeler,
  Executive Vice President, General Counsel
• Aaron L. Cox,
  Exec. VP of Fin. & CFO
• Jane Gonnerman,
  Group VP of Corp. Devel., Chief of Staff & Office of the CEO
• Geoffrey M. Curtis,
  Exec. VP of Corp. Affairs & Chief Communications Officer
• Sean M. Clayton J.D.,
  Exec. VP & Gen. Counsel
• Timothy Ayers,
  Chief Compliance Officer & VP
• Dr. Karin Rosen M.D., Ph.D.,
  Exec. VP of R&D and Chief Scientific Officer
• Miles W. McHugh,
  Chief Accounting Officer & Sr. VP
• Robert Carey,
  EVP & Chief Business Officer
• Jeff Himawan,
  Director
• Gino Santini,
  Director
• Timothy J. Ackerman,
  SVP, Commercial Operations
• Miles W Mc Hugh,
  Sr VP & Princ. Acctg Officer
• George P Hampton,
  See remarks
• Virinder Nohria,
  Director
• Ronald Pauli,
  Director
• Vaere Robert J De,
  EVP & CFO
• Therapeutics Holdings Llc V...,
  10% owner
• Todd N Smith,
  SVP, Marketing & Alliance Mgmt
• David Happel,
  EVP, Commercial Dev & Strategy
• Eric Mosbrooker,
  SVP, Orphan Business Unit
• Shao Lee Lin,
  EVP, Head of R&D and CSO
• Jeff Kent,
  See remarks
• Jeffrey W Bird,
  Director
• Michael Adatto,
  Senior VP Sales & Managed Care
• Bio Ventures Ii Lp Quaker,
  10% owner
• Venture Fund Vi Lp Atlas Ve...,
  
• Peter Johann,
  Director
• Jean Francois Formela,
  Director
• Venture Fund Vi Lp Atlas Ve...,
  
• Woodlands Health Ventures F...,
  10% owner
• Louis C Bock,
  Director
• Hubert Birner,
  Director
• John B Thomas,
  EVP, Corporate Strategy and IR
• David George Kelly,
  EVP, Company Secretary
• John J Kody,
  EVP, Chief Commercial Officer
• Balaji Venkataraman,
  
• Aaron Cox,
  EVP, Chief Financial Officer
• Jeffrey W Sherman,
  EVP and Chief Medical Officer
• Karin Rosen,
  EVP, R&D & CSO
• Elizabeth H.Z. Thompson,
  EVP, Research & Development
• Sean M. Clayton,
  EVP, General Counsel
• Jacopo Leonardi,
  Pres., Global Commercial Ops
• Patrick Mc Ilvenny,
  Chief Accounting Officer